Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Pharmacotherapy for non-alcoholic fatty liver disease: emerging targets and drug candidates
Whether in the form of mitochondrial-derived peptide itself or in terms of sORF, mitochondrial-derived peptide is suitable for research as a therapeutic agent (1)
To date, because of the lack of clear consensus and/or evidence-based guidelines, there is a high degree of variability in the diagnostic approach as well as clinical management of these patients [19]
Advances in peptide therapy have opened new possibilities for supporting muscle growth, improving recovery, and optimizing body composition through the physiological processes
US$ 20.50
US$ 24.45
US$ 26.40
US$ 28.66
